Parkinson's UK invests in drug development

We've awarded the funding to NRG Therapeutics Ltd, an innovative neuroscience company. It will be used to progress the development of the company's most promising drugs. These focus on protecting mitochondria, the batteries that power brain cells.

Following positive progress, this is the third investment Parkinson's UK has made into NRG Therapeutics, bringing the total amount to £2.5m.

The funding comes via our drug development arm, the Parkinson's Virtual Biotech, which is plugging the funding gap to fast-track the projects with the greatest potential to transform the lives of people with Parkinson's.

Significant progress

Dr Arthur Roach, Director of Research at Parkinson's UK, said: 

"We're delighted to further support NRG Therapeutics’ programme to find disease-modifying therapies for Parkinson's.

"We have made significant progress with the company over the past 2 years and share a long-standing commitment to finding a treatment for Parkinson's.

"By partnering with institutions and pharmaceutical companies worldwide that have the tools and expertise to progress projects, the Parkinson's Virtual Biotech enables the most promising discoveries to be developed into new drug treatments to transform the lives of people with Parkinson's."

Dr Neil Miller, co-founder and CEO of NRG Therapeutics, added:

"We are delighted to receive further investment that will enable us to advance our unique drug candidates.

"We are passionate about finding new treatments that offer hope and could change the lives of those with Parkinson's and are encouraged by our preclinical data."